CorMedix Expands Infectious Disease Portfolio with $300M Acquisition of Melinta Therapeutics

New Jersey-based biopharma CorMedix has announced a significant expansion of its infectious disease portfolio through the acquisition of Melinta Therapeutics for $300 million. The deal, expected to close as early as September 1, 2025, marks a transformative step for CorMedix, creating a diversified specialty pharmaceutical company with a focus on acute care and anti-infectives.

Acquisition Details and Strategic Rationale

CorMedix CEO Joe Todisco described the acquisition as "transformational," highlighting the creation of a fully diversified specialty pharmaceutical company with a broad portfolio of commercial and pipeline products. The deal is expected to yield significant operational synergies, with CorMedix estimating annual savings between $35 million and $45 million.

Melinta Therapeutics, a 25-year-old private firm, brings seven marketed products to CorMedix, including six for infectious diseases. The company's flagship product, Rezzayo, approved in 2023, treats potentially fatal yeast infections in the bloodstream.

Christine Ann Miller, CEO of Melinta, emphasized the company's robust commercial infrastructure and expertise within the hospital and acute care ecosystem, citing "significant revenue growth and sustained profitability" over the past five years.

Financial Projections and Growth Opportunities

CorMedix projects that Melinta's products will generate between $125 million and $135 million in revenue in 2025. The company sees further growth potential for Rezzayo, with an anticipated expansion as a prophylaxis for invasive fungal diseases in patients undergoing blood and marrow transplants. Todisco estimates that if approved for this indication, Rezzayo could achieve peak annual sales exceeding $200 million.

Combined with projected sales of $180 million to $200 million for CorMedix's DefenCath in 2025, largely due to a recent deal with a Large Dialysis Organization (LDO), the company forecasts total 2025 revenue between $305 million and $335 million post-acquisition.

Pipeline and Future Developments

CorMedix is also advancing its existing portfolio, with expansion plans for DefenCath as a treatment to reduce central-line bloodstream infections (CLABSIs) in patients receiving total parenteral nutrition through a central venous catheter. A phase 3 study is currently underway, with plans to submit for approval in late 2026 or early 2027.

The acquisition of Melinta Therapeutics significantly bolsters CorMedix's position in the infectious disease market, particularly in the acute care setting. With a diversified product portfolio and strong revenue projections, CorMedix is poised for substantial growth in the coming years.